




The relative strengths and weaknesses of NGM Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NGM Biopharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 110% points. The greatest weakness of NGM Biopharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 379%, being 141% points above the market average of 238%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	355,248	Assets	380,403
Cost of Goods Sold	0	Liabilities	49,684
Intangible Assets	0	Expenses	152,884
Liabilities, Current	39,718	Revenues	103,544
Liabilities, Non-Current	0	Stockholders Equity	330,719
Other Assets	5,680	Net Income	-42,795
Other Compr. Net Income	292	Comprehensive Net Income	-42,649
Other Expenses	0	BaseVar	346,676
Other Liabilities	9,966	ECR before LimitedLiability	315%
Other Net Income	6,545	Economic Capital Ratio	379%
Other Revenues	103,544		
Property and Equipment	19,475		
Research and Development	129,253		
Selling, General and Administrative Expense	23,631		